This ‘preserving the bottom line’ has no difference from signing a normal licence agreement whereby the licencing company does all the work and spends cash on R&D instead of Starpharma.
The major change with this new Venture Capital partnership is that Starpharma get zero dollars now, and zero dollars later if the program gets terminated. Whereas normally cash comes in through licence fees and significant milestone payments.
And let’s face it, the facts are that most drugs worldwide fail during Phase One.
P.S. Case in point being that all three Starpharma partnered programs with AstraZeneca were terminated during Phase One.
- Forums
- ASX - By Stock
- Ann: Investor Webinar Notification SPL Medicxi Partnership
This ‘preserving the bottom line’ has no difference from signing...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
10.5¢ |
Change
0.007(7.14%) |
Mkt cap ! $43.29M |
Open | High | Low | Value | Volume |
9.5¢ | 10.5¢ | 9.5¢ | $8.154K | 83.09K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5102 | 9.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 124847 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5102 | 0.098 |
1 | 6185 | 0.097 |
1 | 20000 | 0.096 |
2 | 528090 | 0.095 |
3 | 40638 | 0.094 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 124847 | 3 |
0.110 | 114609 | 7 |
0.115 | 77331 | 6 |
0.120 | 89055 | 5 |
0.125 | 281784 | 3 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |